Why tube fimbria-end is the favorite site of carcinogenesis in hereditary ovarian cancer A review of literature an our institution experience

Background: Ovarian cancer (OC) is the first cause of death among gynecological malignancies. BRCA mutated women are at risk to develop an OC between 35-60% for BRCA1 and 10-27% in BRCA2 by the age of 70 years. Salpingo-oophorectomy seems to be the only technique that can reduce the risk of OC in this population. Materials and Methods: The authors reviewed PubMed literature about the role of STIC in fimbrial carcinogenesis and describe their 11 cases treated with a total salpingo-oophorectomy (removal of the fallopian tube comprising also the cornual site). Results: No case of STIC or invasive cancer were found in the cornual site of fallopian tube but only one case of STIC was found in the fimbrial end, as literature shows. Conclusion: In this review of the literature, the authors wanted to better understand how carcinogenesis works in the salpinges and if minimal prophylactic surgery can be a safe option.

Ovarian cancer; BRCA mutation; Salpingo-oophorectomy

[1] King M.C., Marks J.H., Mandell J.B., New York Breast Cancer Study Group: “Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2”. Science (New York, N.Y.), 2003, 643.

[2] Yang D., Khan S., Sun Y., Hess K., Shmulvich I., Sood A.K., Zhang W.: “Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer”. JAMA, 2011, 306, 1557.

[3] Buhling K.J., Lezon S., Eulenburg C., Schmalfeldt B.: “The role of transvaginal ultrasonography for detection ovarian cancer in an asymptomatic screening population: a systematic review”. Arch. Gynecol. Obstet., 2017, 295, 1259.

[4] Tang S., Onuma K., Deb P., Wang E., Lytwyn A., Sur M., Daya D.: “Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases”. Int. J. Gynecol. Pathol., 2012, 31, 103.

[5] Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., Medeiros F., et al.: “Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship”. Am. J. Surg. Pathol., 2007, 31, 161.

[6] Jarboe E., Folkins A., Nucci M.R., Kindelberger D., Drapkin R., Miron A., et al.: “Serous carcinogenesis in the fallopian tube: a descriptive classification”. Int. J. Gynecol. Pathol., 2008, 27, 1.

[7] Rabban J.T., Barnes M., Chen L.M., Powell C.B., Crawford B., aloudek C.J.: “Ovarian pathology in risk-reducing salpingooophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma”. Am. J. Surg. Pathol., 2009, 33, 1125.

[8] Seidman J.D., Zhao P., Yemelyanova A.: “Primary peritoneal” highgrade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer”. Gynecol. Oncol., 2011, 120, 470.

[9] Li H.X., Lu Z.H., Shen K., Cheng W.J., Malpica A., Zhang J., et al.: “Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis”. Int. J. Clin. Exp. Pathol., 2014, 7, 848.

[10] Koç N., Ayas S., Uygur L.: “The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer”. Gynecol. Oncol., 2014, 134, 486.

[11] Finch A., Beiner M., Lubinski J., Lynch H.T., Moller P., Rosen B., et al.: “Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation”. JAMA, 2006, 296, 185.

[12] Paley P.J., Swishe”r E.M., Garcia R.L., Agoff S.N., Greer B.E., Peters K.L., Goff B.A.: Occult cancer of the fallopian tube in BRCA- 1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis”. Gynecol. Oncol., 2001, 80, 176.

[13] Hunn J., Rodriguez G.C.: “Ovarian cancer: etiology, risk factors, and epidemiology”. Clin. Obstet. Gynecol., 2012, 55, 3.

[14] Patrono M.G., Iniesta M.D., Malpica A., Lu K.H., Fernandez R.O., Salvo G., Ramirez P.Y.: “Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review”. Gynecol. Oncol., 2015, 139, 568.

[15] Kurman R.J.: “Origin and molecular pathogenesis of ovarian highgrade serous carcinom”. Ann. Oncol., 2013, 24, S16.

[16] Riman T., Persson I., Nilsson S.: “Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence”. Clin. Endocrinol., 1998, 49, 695.

[17] Hansen J.M., Coleman R.L., Sood A.K.: “Targeting the tumour microenvironment in ovarian cancer”. Eur. J. Cancer, 2016, 56, 131.

[18] Chen E.Y., Mehra K., Mehrad M., Ning G., Miron A., Mutter G.L., et al.: “Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube”. J. Pathol., 2010, 222, 110.

[19] Bijron J.G., Seldenrijk C.A., Zweemer R.P., Lange J.G.,Verheijen R.H., Van Diest P.J.: “Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis”. Am J. Surg. Pathol., 2013, 37, 1123.

[20] Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., Saleemuddin A., et al.: “A candidate precursor to serous carcinoma that originates in the distal fallopian tube”. J. Pathol., 2007, 211, 26.

[21] Carcangiu M.L., Radice P., Manoukian S., Spatti G., Gobbo M., Pensotti V., et al.: “Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers”. Int. J. Gynecol. Pathol., 2004, 23, 35.

[22] Piek J.M., van Diest P.J., Zweemer R.P., Jansen J.W., Poort-Keesom R.J., Menko F.H., et al.: “Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer”. J. Pathol., 2001, 195, 451.

[23] Wang Y., Li L., Wang Y., Tang S.N., Zheng W.: “Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis”. Am. J. Transl. Res., 2016, 15, 230.

[24] Fathalla M.F.: “Incessant ovulation and ovarian cancer-a hypothesis re-visited”. Facts Views Vis. Obgyn., 2013, 5, 292.

[25] Malmberg K., Klynning C., Flöter-Rådestad A., Carlson J.W.: “Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development”. Virchows Arch., 2016, 468, 707.

[26] Tomaseti C., Li L., Volgestein B.: “Stem cell divisions, somatic mutations, cancer etiology and cancer prevention”. Science, 2017, 355, 1330.

[27] Wabersich J., Artioli G., Giordano R., De Lorenzi F., Azzarello G., Garbin F.: “Laparoscopic total fallopian tube removal at the time of salpingo-oophorectomy in a BRCA2 positive woman”. Eur. J. Gynecol. Oncol., 2011, 83, 328.

[28] Oliver Perez M.R., Magrina J., Garcia A.T., Jimenez lopez J.S.: “Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high grade serous epithelial carcinoma: a reappraisal”. Surg. Oncol., 2015, 24, 335.

[29] Falconer H., Yin L, Grönberg H., Altman D.: “Ovarian cancer risk after salpingectomy: a nationwide population-based study”. J. Natl. Cancer. Inst., 2015, 27, 107.

[30] Kwon J.S., Tinker A., Pansegrau G., mcAlpine J., Housty M., Mc Cullum M., Gilks C.B.: “Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers”. Obstet. Gynecol., 2013, 121, 14.

[31] Darelius A., Lycke M., Kindblom J.M., Kristjansdottir B., Sundfeldt K., Strandell A.: “Efficacy of salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer: a systematic review”. BJOG, 2017, 124, 880.

[32] Scheib S.A.: “A laparo-endoscopic single site surgical approach to laparoscopic salpingectomy”. J. Minim. Invasive Gynecol., 2017, pii: S1553, 30223.

[33] Committee Opinion no. 620: “Salpingectomy for ovarian cancer prevention. Committee on Gynecologic Practice. Erratum in College Publications (December 2015): Correction”. Obstet. Gynecol., 2016, 127, 405.

[34] NCCN Guidelines: “Genetic/familial high risk assessment breast and ovarian cancer”. Version 2.2017, 7 December 2016.